single new image header


New collaboration between FAMAR and Lavipharm: Joining forces in the production of pharmaceutical products

Athens, 23.01.2024 – FAMAR and Lavipharm, two prominent companies in the pharmaceutical industry, jointly announce their new collaboration. FAMAR is a leading provider of development and manufacturing services for pharmaceutical and cosmetic products (CDMO) and one of the major CDMO players in Europe. Lavipharm, a pioneer in pharmaceutical technology and globally renowned for its expertise in and contribution to enhancing patients’ quality of life for over a century, specializes in research and development, production, import, marketing and distribution of pharmaceuticals and healthcare products in Greece, with a strong international commercial presence.

As part of this new collaboration, FAMAR will undertake production of two pharmaceutical products recently added into Lavipharm’s portfolio. Specifically, FAMAR will serve as the contract manufacturer for Lavipharm’s analgesic pharmaceutical products Lonarid N® and Lonalgal®.
This collaboration confirms the strong developmental impact of both FAMAR and Lavipharm on the pharma industry. It represents a significant development for the domestic market, enhancing the competitiveness of Greek pharmaceutical companies. At the same time, it contributes to increasing the availability of high-quality pharmaceutical products, ensuring their consistent and efficient production, thus enhancing patients’ quality of life.

Nikolaos Papapolitis, Chairman of the Board of Directors of FAMAR A.B.E., stated, “The selection of FAMAR for the production of Lavipharm’s two products reflects our commitment to providing the most innovative products and services that contribute to improving patients’ quality of life. It reaffirms our dedication to consistently remaining the most reliable and dynamic partner throughout our value chain.”

“For Lavipharm, FAMAR is a trusted partner with a global footprint. Their extensive manufacturing facilities and high standards were pivotal factors in our decision. The quantities of tablets for the two pharmaceutical products we recently acquired exceed the available capacity of Lavipharm’s solid dosage production lines,” commented Telemaque Lavidas, Executive Board Member of Lavipharm. “Our collaboration with a company such as FAMAR enables us to further focus on the production of transdermal systems, a core competency that positions Lavipharm among the leaders in the international market.



FAMAR is a leading European provider of pharmaceutical and cosmetic manufacturing and development services. With a legacy of 70 years of technology expertise, FAMAR delivers high-quality dosage forms, including sterile liquids, solids, and semi-solids, creating value for its clients. Operating in Spain, Italy, and Greece, employing over 1,850 people across a network of six production facilities and two R&D centers, FAMAR supplies a wide range of more than 1,700 different products for over 80 international markets. For more information, please visit the official FAMAR website at

About Lavipharm
Listed on the Athens Stock Exchange since 1995 (LAVI), Lavipharm is a pharmaceutical company with a rich legacy in advancing patient care through pioneering healthcare solutions. Since 1911, Lavipharm has a long and successful history of commercial operations in the prescription medicines and OTC markets in Greece. Globally recognized for its expertise in the development and production of transdermal drug delivery systems (TDDS), Lavipharm has a robust presence in major markets around the world, offering patients access to innovative life-improving treatments. For over 110 years, Lavipharm has been enabling people to live healthier and longer lives.